Author:
Madabushi Rajanikanth,Lesko Lawrence,Woodcock Janet
Reference46 articles.
1. Food and Drug Administration The critical path initiative-innovation-stagnation: challenge and opportunity on the critical path to new medical products 2004
2. Food and Drug Administration 2006
3. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework;Biomarkers Definitions Working Group;Clin Pharmacol Ther,2001
4. The food and drug modernization Act of 1997
5. Are surrogate markers adequate to assess cardiovascular disease drugs?;Temple;JAMA,1999